Journal Information
Vol. 109. Issue 9.
Pages 766 (November 2018)
Vol. 109. Issue 9.
Pages 766 (November 2018)
Commentaries
DOI: 10.1016/j.adengl.2018.10.001
Full text access
An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria
Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica
Visits
...
R. Ruiz-Villaverde
Unidad de Dermatología, Hospital Universitario San Cecilio, Granada, Spain
Related content
Actas Dermosifiliogr. 2018;109:771-610.1016/j.adengl.2018.09.011
J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa, A. Gimenez Arnau
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up to 4 times that dose. The introduction of omalizumab into the therapeutic arsenal for CSU brought about a real revolution in the management of this condition. However, the dose recommended in the Summary of Product Characteristics—based on the results of pivotal studies carried out as part of the approval process—is 300 mg/mo for a period of up to 6 months. In the present issue, the Catalan-Balearic working group presents a treatment algorithm to guide the use of omalizumab in the management of CSU. They discuss the various aspects of management related to the rational and evidence-based use of this drug, including candidate population, monitoring tools (Urticaria Activity Score 7 [UAS7] and Urticarial Control Test [UCT]), starting dose and dose adjustment as well as the definition of response and response time.1

In a novel approach, the authors of the algorithm propose the use of an increased dose of 450 or 600 mg every 4 weeks if the licensed doses do not achieve adequate control of disease activity—defined as a UAS7 of 6 or less. A study by the Catalan workgroup showed that 21% of patients require the increased dose to achieve a UAS7 of 6 or less and that 7% did not achieve disease control even with the higher dose. The predictors of partial response to 300 mg and the need for higher doses included prior treatment with ciclosporin, obesity, and age under 57 years.2

This algorithm is of particular interest to dermatologists working in clinical practice.

References
[1]
J. Spertino, E. Rozas Muñoz, L. Curto Barredo, I. Figueras Nart, A. Gimenez Arnau, E. Serra Baldrich, et al.
Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea. Documento de consenso de la “Xarxa d’Urticària Catalana i Balear”.
Actas Dermosifiliogr, 109 (2018),
[2]
L. Curto-Barredo, J. Spertino, I. Figueras-Nart, V. Expósito-Serrano, A. Guilabert, G. Melé-Ninot, et al.
Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria.
Br J Dermatol, 179 (2018), pp. 210-212

Please cite this article as: Ruiz-Villaverde R. Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica. Actas Dermosifiliogr. 2018;109:766.

Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
  • Additional material
Tools
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.